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mTOR and ERRa are key regulators of common
metabolic processes, including lipid homeostasis.
However, it is currently unknown whether these
factors cooperate in the control of metabolism.
ChIP-sequencing analyses of mouse liver reveal
that mTOR occupies regulatory regions of genes on
a genome-wide scale including enrichment at genes
shared with ERRa that are involved in the TCA cycle
and lipid biosynthesis. Genetic ablation of ERRa and
rapamycin treatment, alone or in combination, alter
the expression of these genes and induce the accu-
mulation of TCA metabolites. As a consequence,
both genetic and pharmacological inhibition of
ERRa activity exacerbates hepatic hyperlipidemia
observed in rapamycin-treated mice. We further
show that mTOR regulates ERRa activity through
ubiquitin-mediated degradation via transcriptional
control of the ubiquitin-proteasome pathway. Our
work expands the role of mTOR action in metabolism
and highlights the existence of a potent mTOR/ERRa
regulatory axis with significant clinical impact.
INTRODUCTION
The mammalian target of rapamycin (mTOR), a phosphatidylino-
sitol 3 kinase (PI3K)-related serine/threonine kinase, plays a
major role in cell growth, proliferation and survival, in part by
controlling messenger RNA (mRNA) translation (Wullschleger
et al., 2006). mTOR is the core component of two distinct
complexes: mTORC1 (complex 1) and mTORC2 (complex 2).
mTORC1 is considered to be a central integrator of a wide range
of physiological cues such as amino acid levels, energy status,
and oxygen levels in order to promote cellular growth and prolif-
eration (Gulati and Thomas, 2007). Themajority of these different
stimuli (except amino acids) signals to mTORC1 through the586 Cell Metabolism 17, 586–598, April 2, 2013 ª2013 Elsevier Inc.modulation of Tuberous sclerosis complex 1 and 2 (TSC1
and TSC2) activity (Gulati et al., 2008). mTORC1 is also the
only complex sensitive to acute rapamycin treatment and has
been shown to control protein synthesis via the S6 kinase/S6
axis and 4E-BP1 phosphorylation (Sonenberg and Hinnebusch,
2009).
At a physiological level, the mTORC1 signaling pathway has
been described to play an important role in the control of energy
metabolism, particularly in lipid biosynthesis (Inoki et al., 2012).
This notion has emerged from observations of clinical trials
involving rapamycin or rapalog administration. Side effects of
these drugs have been reported such as hyperlipidemia and
hypercholesterolemia and activation of gluconeogenesis in liver,
a major organ for lipid biosynthesis (Houde et al., 2010; Levy
et al., 2006; Morrisett et al., 2002). Furthermore, rodents treated
with rapamycin and rapalogs develop nonalcoholic fatty livers
(NAFLs) associated with elevated free fatty acid (FFA) levels (Pat-
senker et al., 2011). Themechanism by which inhibitors of mTOR
generate an increase in lipogenesis involves a multitude of
factors that includes PPARg, SREBP1, and/or lipin1 that inter-
play with each other to regulate the lipogenic gene program
(Peterson et al., 2011).
Aside from the well-established role of mTOR as a kinase in
signaling cascades, several studies have shown that mTOR
can shuttle between the cytoplasm and nucleus (Bachmann
et al., 2006; Kim and Chen, 2000; Rosner and Hengstschla¨ger,
2008; Zhang et al., 2002). Standard chromatin immunoprecipita-
tion (ChIP) studies revealed that mTOR is recruited to DNA and
can interact with various transcription factors such as YY1 and
MAF1 to modulate gene expression at a transcriptional level
(Cunningham et al., 2007; Kantidakis et al., 2010). Although
both mTORC1 and mTORC2 components have been identified
in the nucleus (Rosner and Hengstschla¨ger, 2008), mTOR
recruitment to DNA has been shown to be sensitive to amino
acid levels and rapamycin treatment (Tsang et al., 2010), indi-
cating that mTOR occupancy on chromatin is mTORC1-depen-
dent. In addition, TOR1 has been shown to bind DNA in yeast (Li
et al., 2006), and Raptor occupancy on chromatin has been
observed previously (Cunningham et al., 2007; Shor et al.,
2010). Although the first de novo mTOR target genes identified
Figure 1. mTOR Is a Transcriptional Regulator of Metabolic Pathways
(A) Mapping of mouse liver mTOR ChIP-seq peaks across the genome. TTS (transcription termination site) represents binding peaks found 100 bp to + 1 kb
relative to the nearest TSS.
(B) Histogram illustrating the distribution of mTORChIP-seq peaks ± 10 kb relative to the TSS of the nearest gene. Peaks were combined into 1,000 bp bins. Inner
histogram shows peaks ± 1 kb relative to the TSS of the nearest gene. Peaks were combined into 100 bp bins.
(C) Subset of significantly enriched canonical pathways identified by IPA analysis of mTOR ChIP-seq targets found within ± 10 kb relative to the TSS of the
nearest gene.
(D) Graphical view of mTOR ChIP-seq binding peaks (tag densities) around the TSSs of the genes Polr3e, Tsc1, Pten, and Ndufa6 obtained from the UCSC
genome browser. Arrows show direction of transcription.
(legend continued on next page)
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ERRa/mTOR Regulatory Axis in Liverwere polymerase III (pol III)-dependent genes, mTOR was later
shown to bind to the gene encoding dystrophin, and two genes
encoding proteins involved in mitochondrial function, cyto-
chrome C and the coactivator PGC-1a (Cunningham et al.,
2007; Kantidakis et al., 2010; Risson et al., 2009; Shor et al.,
2010; Tsang et al., 2010). While these findings suggested
a distinct mechanism by which mTOR could regulate energy
metabolism, the limited number of mTOR target genes identified
thus far currently prevents a full appreciation of the importance of
the potential role of mTOR as a transcriptional regulator.
Estrogen-related receptor a (ERRa, NR3B1) is an orphan
nuclear receptor that plays a crucial role in the transcriptional
control of mitochondrial function and energy metabolism (De-
blois and Gigue`re, 2011; Eichner and Gigue`re, 2011; Gigue`re,
2008; Villena and Kralli, 2008). The identification of the first
ERRa target gene, Acadm, encoding medium-chain acyl coen-
zyme A, suggested a potential role for ERRa in the control of
lipid metabolism (Sladek et al., 1997; Vega and Kelly, 1997).
Mice lacking ERRa are lean and resistant to weight gain under
a high-fat diet (Luo et al., 2003). Furthermore, ERRa is a regu-
lator of glucose homeostasis. ERRa-null mice exhibit time-
dependent hypoglycemia and hypoinsulinemia with enhanced
glucose uptake due to increased insulin sensitivity (Dufour
et al., 2011). In agreement with the findings obtained in
ERRa-null mice, administration of a highly selective ERRa
inverse agonist (compound 29, C29) in rodent models of obesity
and diabetes results in improved insulin sensitivity and glucose
tolerance accompanied by reduced circulating glucose, FFA,
and triglyceride (TG) levels (Patch et al., 2011). These observa-
tions have reinforced the concept that ERRa is an essential
factor in the control of energy metabolism and thus a potential
therapeutic target for the treatment of metabolic disorders
(Gigue`re, 2008).
While mTOR and ERRa are considered as key regulators of
metabolism, particularly in mitochondrial function and lipid
homeostasis, it is currently unknown to which extent the two
signaling pathways intersect. Herein, we demonstrate that
mTOR targets metabolic genes on a genome-wide scale and
positively regulates ERRa expression and activity via transcrip-
tional control of the ubiquitin pathway. We further show that
the mTOR/ERRa axis is of physiological significance as it plays
a key role in the development of rapamycin-induced NAFL.
RESULTS
A Transcriptional Network Linking mTOR and ERRa to
the TCA Cycle and Lipid Metabolism
To explore whether mTOR plays a global role as a transcriptional
regulator and its potential interplay with the ERRa regulatory
pathway, we performed mTOR and ERRa ChIP-sequencing
(ChIP-seq) analyses using chromatin obtained frommouse livers
(Table S1, Table S2, Table S3, and Table S4 available online).
Analysis of the data sets revealed 9,469 peaks bound by
mTOR. The distribution of these binding events across the(E) Venn diagrams illustrating the overlap in number of binding peaks and unique
(F) Number of ChIP-seq targets bound by either ERRa (red), mTOR (blue) or b
*p < 0.05.
See also Figures S1–S3 and Table S1, Table S2, Table S3, Table S4, and Table
588 Cell Metabolism 17, 586–598, April 2, 2013 ª2013 Elsevier Inc.genome is shown in Figure 1A. We first investigated the extent
of mTOR recruitment to pol-III-driven genes by comparing our
mTOR ChIP-seq data set with a recently published pol III
ChIP-seq data set (Carrie`re et al., 2012). Comparison of the
two data sets revealed that 44% of the pol-III-bound RNA-
encoding genes are also bound bymTOR (Figure S1A). Our anal-
ysis demonstrates a striking preference for shared pol III/mTOR
occupancy of 4.5S RNAs (100%) and transfer RNAs (tRNAs;
76%) compared to SINEs (3%) (Table S5). Standard ChIP anal-
ysis validates that mTOR is recruited to different classes of
RNA-encoding genes bound by pol III (Figures S1B and S1C).
We next examined the mTOR ChIP-seq data set for mTOR
binding to pol-II-transcribed genes. Validation by standard
ChIP analysis of a subset of these genes is shown in Figure S1D.
A total of 4,055 of the 9,469mTOR-bound peaks associated with
54% (2,969) of the unique genes identified are found within ± 10
kb of the transcriptional start sites (TSSs) of genes (Figure 1B).
These binding events have a preference for a region sur-
rounding ± 1kb of TSSs of genes (Figures 1B and S1E). Analysis
of mTOR target genes revealed an enrichment in physiological
functions related to protein metabolism and turnover including
the protein ubiquitination pathway, assembly of RNA pol III
complex and tryptophan metabolism (Figure 1C). We also found
a significant enrichment of genes involved in the PI3K/AKT, Wnt/
b-catenin, and insulin receptor signaling pathways, findings that
are consistent with the known roles of mTORC1. In addition,
mTOR is significantly recruited at genes involved in oxidative
phosphorylation (OXPHOS) (Figure 1C). Prototypic binding
profiles illustrating mTOR recruitment to genes involved in these
various processes are shown in Figure 1D. Next, we investigated
whether mTOR occupancy of pol-III- and pol-II-transcribed
genes is dependent on the presence of the mTORC1-specfic
protein, Raptor. mTOR ChIP assays performed on livers from
Raptor+/ mice revealed less recruitment of mTOR to target
genes when Raptor levels are diminished in vivo (Figures S2A
and S2B). Known and de novo motif finding analyses did not
identify with high confidence a consensus motif specifically
associated with mTOR binding events.
Mouse liver ERRa ChIP-seq analyses identified 23,226 peaks
significantly enriched for the sequence 30-TCAAGGTCA-50, the
known ERRa consensus binding motif (Sladek et al., 1997) (Fig-
ure S3A). Nearly 50% of the peaks were found within intronic
regions with a substantial preference for the first intron close to
the TSS (Figures S3A and S3B). A total of 8,077 ERRa-bound
peaks are foundwithin ± 10 kb of the TSSs of genes correspond-
ing to 43% (2,373) of the unique genes identified (Figure S3C).
Investigation of a potential crosstalk between ERRa and mTOR
by comparing the two ChIP-seq data sets did not show a signif-
icant overlap in binding peaks implying that ERRa and mTOR do
not interact with each other on DNA (Figure 1E). In contrast,
a significantly large proportion of mTOR target genes (3,687)
are also targeted by ERRa, indicating that the two factors
regulate common biological functions. As shown in Figure 1F,
ERRa and mTOR are commonly recruited to genes involved ingenes identified in the ERRa and mTOR mouse liver ChIP-seq data sets.
oth (green) within metabolic pathways identified by IPA analysis are shown.
S5.
Figure 2. Crosstalk between mTOR and ERRa in the Transcriptional
Control of the TCA Cycle and Lipogenesis
(A) Schematic illustrating the ChIP-seq targets bound by ERRa (red), mTOR
(blue), or both (green) implicated in the TCA cycle and lipid biosynthesis.
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Cmetabolic processes, including OXPHOS, the TCA cycle, glycol-
ysis/gluconeogenesis, and lipid metabolism.
We next sought to determine the impact of mTOR and ERRa
signaling on the hepatic expression of a subset of mTOR and/
or ERRa targeted genes involved in the TCA cycle and lipogen-
esis (Figure 2A). Our results uncovered three different classes
of genes based on their response to rapamycin inhibition of
mTOR and/or ablation of ERRa. First, we identified genes that
are only affected by the loss of ERRa that includes Sdhd and
Sucla2whose gene products are enzymes of the TCA cycle (Fig-
ure 2B). Second, Gpam and Elovl6, whose gene products are
implicated in the lipogenic pathway, were classified as being
only sensitive to rapamycin (Figure 2C). Rapamycin treatment re-
sulted in increased mRNA levels of these two genes irrespective
of the genotype of the mice. Finally, Sdhb and Fasn, whose gene
products are involved in the TCA cycle and in the lipid biosyn-
thesis pathway, respectively, were classified based on their
responsiveness to a combined loss of ERRa and mTOR activity.
Sdhb responded only to a combined loss in both ERRa and
mTOR activity while Fasn responded in an additive manner to
both ERRa andmTORmodulation (Figure 2D). In particular, livers
of ERRa-null micewere found to have nearly 2.5 timesmore Fasn
levels compared to wild-type (WT) and these mRNA levels nearly
doubled again in the presence of rapamycin. As Fasn is a direct
target of ERRa but not mTOR, the further increase in Fasn tran-
script levels in ERRa-knockout (KO)mice by rapamycin indicates
that other transcription factors could also play a role in the
control of this gene. Indeed, the effects of rapamycin treatment
and/or loss of ERRa on Pparg expression is similar to that
observed for Fasn (Figure 2E). While rapamycin treatment did
not affect Srebf1 (encoding Srebp1) expression, levels were
nearly tripled in ERRa-null mice. In addition, an induction of
Ppara levels was observed in the ERRa-null livers, which could
be a response to the compensatory increase of Ppargc1a ex-
pression (Figure S4).
Loss of ERRa Activity Results in Impaired TCA Cycle
Activity and Exacerbates Rapamycin-Induced NAFL
We next explored the biological consequence of both rapamy-
cin-mediated inhibition of mTOR activity and loss of ERRa in
mouse liver. First, we examined that impact on TCA cycle activity
by quantifying hepatic TCA cycle intermediates (Figure 3). In
addition, the expression level of one gene for every step of the
TCA cycle was measured. Of note, most of these genes belong
to the subgroup of genes responding to both rapamycin and the
absence of ERRa (Figure 2D). Treatment of WT mice with rapa-
mycin did not significantly affect the levels of the TCA intermedi-
ates measured. In contrast, ERRa-null mice exhibit higher levels(B) Quantitative RT-PCR (qRT-PCR) analysis of metabolic genes that are
ERRa-responsive in livers isolated fromWT and ERRa-null mice treatedwith or
without rapamycin for 7 days. Data are normalized to Hprt levels. Error bars
represent ± SEM. *p < 0.05.
(C) qRT-PCRanalysis ofmetabolic genes that are rapamycin-responsive. Error
bars represent ± SEM. *p < 0.05.
(D) qRT-PCR analysis of metabolic genes that are responsive to a combined
loss of ERRa and rapamycin. Error bars represent ± SEM. *p < 0.05.
(E) qRT-PCR analysis of metabolic transcription factors that are responsive to
ERRa and/or rapamycin. Error bars represent ± SEM. *p < 0.05.
See also Figure S4 and Table S8.
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Figure 3. Metabolic Crosstalk between mTOR and ERRa in the Production of TCA Cycle Intermediates
Quantification of TCA cycle intermediates by either GC/MS or NMR analyses of livers collected from wild-type and ERRa-KO mice administered rapamycin
(10 mg/kg) or vehicle on a daily basis by intraperitoneal injection during a 7 day period (inside gray area). qRT-PCR analysis was performed on the same livers
used for metabolomics studies, and one TCA cycle gene at every step in the cycle is shown as boxed graphs. qRT-PCR data are normalized to Hprt levels. Error
bars represent ± SEM. *p < 0.05. See also Table S8.
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ERRa-null mice resulted in increased levels of cis-aconitate and
succinate with a trend for higher 2-oxo-glutarate levels com-
pared to untreated ERRa-KO mice. Interestingly, intermediates
did not accumulate in later stages of the TCA cycle, and no
further accumulation of citrate was observed. The repressed
gene expression profiles in the ERRa-KO livers of the enzymes
corresponding to the transitions from citrate through to fumarate
suggests that the specific metabolite accumulation observed
indicates the outcome of an ERRa-dependent blunted TCA cycle
between these steps.
Metabolomic data suggests that rapamycin treatment in
ERRa-KO mice might result in increased incorporation of citrate590 Cell Metabolism 17, 586–598, April 2, 2013 ª2013 Elsevier Inc.into the lipogenic pathway. To test this hypothesis, we per-
formed histological and biochemical analyses on the corre-
sponding livers. As expected, rapamycin treatment reduced
the phosphorylation of the ribosomal S6 protein in both geno-
types (Figure 4A). In addition, we found that the phosphorylation
of AKT, a target of mTORC2, was higher in all of the rapamycin-
treated mice, a phenomenon previously noted in the liver (Sar-
bassov et al., 2006). There were no noticeable differences in
basal S6 or AKT phosphorylation between the WT and KO
mice, suggesting that the loss of ERRa does not affect the
mTOR signaling pathway. Surprisingly, rapamycin treatment in
WT mice nearly completely abolished ERRa protein levels (Fig-
ure 4A) in a manner that cannot be explained by the modest
Figure 4. Rapamycin-Induced NAFL Is Exac-
erbated by Genetic and Pharmacological
Inhibition of ERRa
(A) Western blot analysis of total ERRa, phospho-S6
(S235/S236), total S6, phospho-AKT (S473), and total
AKT levels in mouse livers collected from wild-type
and ERRa-KO mice treated with or without rapamy-
cin for 7 days. Actin levels are shown as a loading
control.
(B) Representative hematoxylin and eosin (H&E) and
oil red O staining of liver sections from wild-type and
ERRa-KO mice administered rapamycin (10 mg/kg)
or vehicle on a daily basis by intraperitoneal injection
during a 7 day period. Scale bars represent 40 mm
and 160 mm (inset).
(C) Measurement of hepatic FFAs of WT and
ERRa-null mice after a 7 day treatment of rapamycin
or vehicle. Error bars represent ± SEM. *p < 0.05.
(D) Measurement of hepatic TGs of WT and
ERRa-null mice as in (C).
(E) Measurement of hepatic cholesterol levels of WT
and ERRa-null mice as in (C).
(F) Measurement of serum TG levels in WT and
ERRa-null mice as in (C).
(G) qRT-PCR analysis of genes at each of the first six
steps in the conversion of citrate to TGs on livers
isolated from WT and ERRa-null mice treated with or
without rapamycin for 7 days. Data are normalized to
Hprt levels. Error bars represent ± SEM. *p < 0.05.
(H) Representative H&E and oil red O staining of liver
sections from WT mice administered rapamycin
(10mg/kg), the ERRa inverse agonist C29 (10mg/kg),
or both on a daily basis by intraperitoneal injection
during a 10 day period. Scale bars represent 40 mm
and 160 mm (inset).
See also Figures S4 and S5 and Table S8.
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Figure 5. ERRa Expression and Activity Is Regulated by the mTOR Signaling Pathway
(A) qRT-PCR expression analysis of mTOR and Esrra expression after treatment of Hepa 1-6 cells with a pool of siRNAs against mTOR for 96 hr. Data are
normalized to Hprt levels. Error bars represent ± SEM. *p < 0.05.
(B) Western blot analysis of total ERRa, mTOR, phospho-S6 (S235/S236), and phospho-AKT (S473) in Hepa 1-6 cells treated with a pool of siRNAs for 96 hr
against mTOR. Actin levels are shown as a loading control.
(C) Western blot analysis shows loss of ERRa protein levels in HeLa cells infected with an shRNA targeting mTOR for 72 hr. Actin levels are shown as a loading
control.
(D) Total ERRa, phospho-S6 (S235/S236), total S6, phospho-AKT (S473), and total AKT protein levels in Hepa 1-6 cells in response to a 24 hr treatment of torin 1.
Tubulin levels are shown as a loading control.
(E) Western blot analysis of total ERRa, phospho-S6 (S235/S236), total S6, phospho-AKT (S473), and total AKT levels in mouse livers collected from WT mice
treated with vehicle or torin 1 on a daily basis by intraperitoneal injection during a 2 day period. Actin levels are shown as a loading control.
(F) Western blot analysis of total ERRa, phospho-S6 (S235/S236), total S6, and Raptor levels in Hepa 1-6 cells infected with control shRNA or shRNA directed
against Raptor for 7 days. Actin levels are shown as a loading control.
(G) Western blot analysis of total ERRa, phospho-S6 (S235/S236), total S6, and Raptor protein levels in wild-type and Raptor+/mouse livers. Tubulin levels are
shown as a loading control.
(H) Esrra mRNA expression levels in Hepa 1-6 cells cells treated with rapamycin or vehicle for 48 hr. Data are normalized to Hprt levels. Error bars represent ±
SEM. *p < 0.05.
(I) Total ERRa, phospho-S6 (S235/S236), total S6, phospho-AKT (S473), and total AKT protein levels in Hepa 1-6 cells in response to a 48 hr treatment of
rapamycin. Actin levels are shown as a loading control.
(J) Standard ChIP analyses of mTOR and ERRa binding to their respective metabolic target genes in Hepa 1-6 cells treated with rapamycin or vehicle as a control
for 48 hr.
(K) qRT-PCR analysis of Ogdh and Idh3a expression in Hepa 1-6 cells treated with rapamycin or vehicle for 48 hr. Data are normalized to Hprt levels. Error bars
represent ± SEM. *p < 0.05.
(legend continued on next page)
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observations suggest that rapamycin affects ERRa expression
predominantly at the posttranslational level. Histological exami-
nation showed a greater microvesicular accumulation of lipids in
ERRa-KO livers compared to WT in response to rapamycin (Fig-
ure 4B). Although no significant difference in basal liver FFAs and
TGs were identified in ERRa-null livers, ERRa-KO mice treated
with rapamycin exhibited an increase in hepatic FFA and TG
content compared to rapamycin treated WT mice (Figures 4C
and 4D). In contrast, no differences in liver cholesterol levels
were observed between the four groups (Figure 4E). Moreover,
rapamycin-treated mice had significantly more circulating serum
TG levels independent of the genotype (Figure 4F). Next, we
analyzed the mRNA levels of the genes controlling the first six
steps involved in the conversion of citrate to TGs (Figure 4G).
Overall, levels of Acly as well as Fasn and Scd1 were found to
be highest in ERRa-null mice treated with rapamycin. Of interest,
loss of Scd1 expression in mice is associated with decreased
lipogenesis and increased fatty acid oxidation (FAO), leading to
a protective effect against the development of hepatic steatosis
(Cohen et al., 2002). Furthermore, Acaca (encoding ACC1)
mRNA levels were significantly increased in both WT and
ERRa-null mice in a rapamycin-dependent manner reflecting
the development of NAFLs in these mice (Figure 4G). No differ-
ences in Acacb (encoding ACC2) levels were found. However,
rapamycin induced both phosphorylation of AMPKa and its
target ACC (Figure S5A). Despite an apparent attempt to inhibit
lipogenesis and stimulate FAO, these mice nonetheless develop
NAFLs. For further validation of our findings that rapamycin treat-
ment in mice deficient in ERRa activity worsens the development
of NAFLs, mice were injected with rapamycin and/or the ERRa
inverse agonist C29 (Patch et al., 2011). As observed in mice
with a genetic ablation of ERRa, larger vesicles and higher accu-
mulation of lipids were found in livers of cotreated mice (Fig-
ure 4H). Moreover, we investigated whether the potent mTOR
inhibitor, torin 1, capable of suppressing both mTORC1 and
mTORC2 complexes can also exacerbate the development
of NAFLs in mice lacking ERRa. Because of the unexpected
lethal toxicity of torin 1 administration specifically observed in
ERRa-null mice likely due to lipotoxicity, livers were collected
after a 2-day administration of torin 1. Histological analysis of
liver sections revealed severe lipid accumulation in torin
1-treated ERRa-null mice (Figure S5B). Taken together, these
data exclude the possibility that the increased lipid accumulation
in the livers of rapamycin- and torin-1- treated ERRa-null mice is
due to a life-long absence of ERRa.
mTOR Signaling Controls ERRa Expression and
Transcriptional Activity
The observation that the expression of ERRa is regulated in a
rapamycin-sensitive manner led us to investigate the molecular
link between mTORC1 signaling and ERRa transcriptional
activity. At the mRNA level, treatment of the Hepa 1-6 mouse(L) Activation ofmTOR signaling in TSC2-null MEFs results in increased ERRa and
Actin levels are shown as a loading control.
(M)Western blot analysis shows loss of ERRa and phospho-S6 (S235/S236) prote
Actin levels are shown as a loading control.
See also Tables S6–S8.
Ccell line with small interfering RNAs (siRNAs) against mTOR
resulted in a modest but significant reduction (20%) in ERRa
transcript levels (Figure 5A). Consistent with what we observed
previously in livers of rapamycin-treated mice, ERRa protein
expression was strongly abrogated in cells lacking mTOR
(Figure 5B). Similar results were obtained in a human cell line
(HeLa) infected with short hairpin RNA (shRNA) directed against
human mTOR (Figure 5C). Moreover, inhibition of both mTORC1
andmTORC2 activity by torin 1 treatment in Hepa 1-6 cells and in
mice also results in a significant reduction in ERRa protein levels
(Figures 5D and 5E). Targeted disruption of mTORC1 signaling in
Hepa 1-6 cells infected with mouse specific shRNA against
Raptor also resulted in loss of ERRa protein levels (Figure 5F).
Similarly, a reduction in ERRa protein expression was observed
in livers of Raptor+/ mice compared to WT (Figure 5G). Treat-
ment of Hepa 1-6 cells with the mTORC1 inhibitor, rapamycin,
results in a similar decrease in ERRa mRNA levels to that
observed previously with siRNAs against mTOR (Figure 5H).
Interestingly, rapamycin treatment also resulted in a strong
decrease in ERRa protein levels in these cells (Figure 5I). Next,
we sought to determine whether the effects of rapamycin on
ERRa also altered recruitment of ERRa to its target genes. First,
we determined whether rapamycin treatment in Hepa 1-6 cells
alters mTOR recruitment to DNA. Indeed, we observed a reduc-
tion in mTOR binding to metabolic target genes in response to
rapamycin treatment (Figure 5J). In parallel, we found decreased
ERRa recruitment to its own promoter, Esrra, as well as to that of
two metabolic targets, Ogdh and Idh3a, in rapamycin-treated
cells (Figure 5J), coinciding with the reduction in themRNA levels
of these genes in Hepa 1-6 cells (Figures 5H and 5K) or mouse
liver (Figure 3) exposed to rapamycin. To further validate the
influence of mTORC1 on ERRa expression, we tested the effects
of manipulatingmTORC1 activity by either a genetic approach or
physiological stimuli. Constitutive activation of mTORC1 sig-
naling in TSC2-null mouse embryonic fibroblasts (MEFs) results
in an increase in ERRa levels (Figure 5L), while inhibition of
mTORC1 activity via starvation of Hepa 1-6 cells of either amino
acids or glucose abolished ERRa expression in those cells
(Figure 5M).
Rapamycin Induces Ubiquitin/Proteasome-Mediated
ERRa Degradation
We next explored the underlying mechanism responsible for
the striking decrease in ERRa protein expression in response
to inhibition of mTOR signaling. To test whether mTOR inhibition
contributes to ERRa degradation via a ubiquitin-dependent
mechanism, we first examined the effect of mTOR silencing on
whole-cell protein ubiquitination (Figure 6A). mTOR knockdown
resulted in decreased phospho-S6, mTOR, and ERRa protein
levels associated with a higher amount of ubiquitinated proteins
compared to the cells transfected with siCtrl. In the presence of
rapamycin, nuclear ERRa was depleted after drug treatment
(Figure 6B). Of note, rapamycin treatment resulted in decreasedphospho-S6 (S235/S236) protein levels as determined bywestern blot analysis.
in levels in Hepa 1-6 cells after a 24 hr starvation of total amino acids or glucose.
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Figure 6. mTOR-Mediated Degradation of ERRa via a Ubiquitin/Proteasomal-Dependent Mechanism
(A) Western blot analysis of total ubiquitinated proteins, mTOR, phospho-S6 (S235/S236), and ERRa in Hepa 1-6 cells treated with a pool of siRNAs against
mTOR. Actin levels are shown as a loading control.
(B) Western blot analysis of ERRa, phospho-S6 (S235/S236), total S6, and ubiquitinated proteins in nuclear and cytoplasmic fractions of Hepa 1-6 cells treated
with rapamycin or vehicle for 48 hr. Lamin B1 and tubulin levels are shown as loading controls for nuclear and cytoplasmic fractions, respectively.
(C)Western blot analysis of ERRa expression in Hepa 1-6 cells treatedwith cycloheximide at the indicated time points. Actin levels are shown as a loading control.
(D) Hepa 1-6 cells were treated with or without the proteasome inhibitor, MG132 for 24 hr. Western blot analysis shows an accumulation of ubiquitinated proteins
and ERRa in the presence of MG132. Actin levels are shown as a loading control.
(E) Immunoprecipitation studies show ERRa ubiquitination in Hepa 1-6 cells treated with MG132 for 24 hr. Actin levels are shown as a loading control.
(F) Western blot analysis shows that MG132 treatment rescues rapamycin-mediated inhibition of ERRa and phospho-S6 (S235/S236) levels in Hepa 1-6 cells.
(G) Graphical view of mTOR ChIP-seq binding peaks (tag densities) around the TSSs of Ubb and Stub1 (CHIP) obtained from the UCSC genome browser. Arrow
shows direction of transcription.
(H) Standard ChIP analysis of mTOR recruitment to Ubb and Stub1 (CHIP) target genes in Hepa 1-6 cells treated with rapamycin or vehicle as a control
for 48 hr.
(I) qRT-PCR analysis ofUbb andStub1 (CHIP) mRNA levels in Hepa 1-6 cells treatedwith siRNAs against mTOR for 96 hr. Data are normalized toHprt levels. Error
bars represent ± SEM. *p < 0.05.
(J) Loss of mTOR signaling in Hepa 1-6 cells via rapamycin treatment leads to an increase in bothUbb and Stub1 (CHIP) mRNA levels. Data are normalized toHprt
levels. Error bars represent ± SEM. *p < 0.05.
(K) Western blot analysis shows increased Stub1 protein levels in Hepa 1-6 cells treated with rapamycin for 48 hr. Actin levels are shown as a loading control.
(L) Total ERRa and ubiquitinated protein levels in Hepa 1-6 cells treated with a pool of siRNAs against Ubb for 72 hr. Actin levels are shown as a loading control.
(M) Total ERRa and Stub1 (CHIP) protein levels in Hepa 1-6 cells treated with a pool of siRNAs against Stub1 for 72 hr. Tubulin levels are shown as a loading
control.
(legend continued on next page)
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ERRa/mTOR Regulatory Axis in LiverP-S6 in both cytoplasmic and nuclear fractions. In parallel, we
noticed an accumulation of ubiquitinated proteins in both cellular
fractions in response to the mTOR inhibitor. These data indicate
that mTOR inhibition leads to an activation of the ubiquitin path-
way in hepatocytes. We next determined the turnover of ERRa in
hepatocytes. Cycloheximide treatment shows that the ERRa
protein has a relatively short half-life (4 hr) (Figure 6C). Inhibition
of the proteasome with MG132 led to an increase in both ERRa
and its ubiquitinated form (Figures 6D and 6E). Interestingly,
MG132 treatment was also found to protect against rapamy-
cin-induced ERRa protein degradation and rescued some of
the rapamycin inhibition of S6 phosphorylation (Figure 6F).
Next, we investigated whether mTOR regulates the protein
ubiquitination pathway directly, the most significantly enriched
canonical pathway identified among the mTOR ChIP-seq target
genes (Figure 1C). Binding peak profiles of mTOR for the genes
Ubb and Stub1, also known as CHIP, encoding ubiquitin B and
an E3-ubiquitin protein ligase, respectively, are shown in Fig-
ure 6G. To determine whether mTOR regulates the expression
of Ubb and Stub1, we first show that mTOR recruitment to the
Ubb and Stub1 genes is rapamycin sensitive (Figure 6H).
Second, Hepa 1-6 cells treated with siRNAs directed against
mTOR led to an upregulation in both Ubb and Stub1 expression
(Figure 6I). Similarly, rapamycin treatment in Hepa 1-6 cells re-
sulted in increased mRNA levels of both Ubb and Stub1 with
a parallel increase in Stub1 and total ubiquitin protein levels
(Figures 6J and 6K). Moreover, siRNA-mediated knockdown
or overexpression of either Ubb or Stub1 in Hepa 1-6 cells re-
sulted in an increase or decrease in ERRa protein levels,
respectively (Figures 6L–6O). Our results demonstrate that
mTOR signaling controls ERRa degradation by regulating the
nonlysosomal ubiquitin/proteasome system at the transcrip-
tional level (Figure 6P).
DISCUSSION
ERRa is well known to play a pivotal role in the control of energy
metabolism and, like mTOR, is a potential therapeutic target for
the treatment of metabolic disorders. The work presented herein
reveals that mTOR and ERRa bind to and control the expression
of a large set of both unique and common genes implicated in
mitochondrial function and the lipid biosynthesis pathway.
Furthermore, we show that rapamycin inhibition of mTOR leads
to the degradation of ERRa through a proteasome-dependent
mechanism, indicating that ERRa is integrated into the mTOR
signaling pathway. The finding that rapamycin represses ERRa
expression identifies an additional molecular link between
mTOR and ERRa in the control of energy metabolism. Our
data suggest that the metabolic side effects that occur in
response to rapamycin treatment are mediated in part through
the reduction in ERRa expression. Loss of ERRa activity via
genetic or pharmacological inhibition exacerbates the develop-
ment of rapamycin-induced NAFL.(N) Total ERRa and ubiquitinated protein levels in Hepa 1-6 cells treated with eithe
as a loading control.
(O) Total ERRa and Stub1 (CHIP) protein levels in Hepa 1-6 cells treated with eit
(P) Schematic representation highlighting the molecular link between rapamycin
See also Figure S6 and Tables S6 and S8.
CThe absence of ERRa activity results in a significant dysregu-
lation of the expression of genes involved in the TCA cycle and
lipogenic pathways in the liver resulting in a seemingly increased
potential for hepatic de novo lipogenesis. Despite a tendency for
more FAs and TGs, ERRa-null mice were not found to signifi-
cantly accumulate lipids in the liver. In addition, no increase in
circulating TGs was found, suggesting that ERRa-null mice
maintain lipid homeostasis by activating compensatory mecha-
nisms to metabolize lipids. While elevated levels of the tran-
scription factors Pparg and Srebp1, both capable of inducing
lipogenic gene programs were observed, loss of ERRa also
results in a parallel induction in Ppargc1a and Ppara levels, two
factors known to play a vital role in stimulating FAO. Moreover,
ERRa-null mice display a mild increase in both p-AMPKa
and p-ACC levels suggesting a decrease in the conversion of
acetyl-CoA to malonyl-CoA and a consequent activation of
FAO. Although ERRa-null mice accumulate TCA cycle intermedi-
ates and thus seem to have decreased mitochondrial function,
they do not exhibit dyslipidemia under normal conditions.
Further studies are needed to identify the exact mechanisms
by which loss of ERRa activity alone does not lead to the devel-
opment of NAFLs. On the other hand, rapamycin treatment of
ERRa-null mice exacerbated the observed NAFL in rapamycin-
treated WT mice. Although rapamycin treatment in both WT
and ERRa-null mice led to a robust increase in p-AMPKa and
p-ACC levels, this compensatory mechanism to inhibit lipogen-
esis and activate FAO was not sufficient to prevent hyperlipid-
emia in these mice. Rapamycin-treated ERRa-null mice were
found to display higher mRNA levels of Acly, Fasn, and Scd1
involved in lipogenesis compared to rapamycin-treated WT
mice. Despite the greater accumulation of lipids in ERRa-null
mice compared to WT in response to rapamycin, no difference
in circulating TG levels was found between the mice, indicating
a possible decreased efficiency in mice lacking ERRa to export
lipids from the liver. Dysregulation in FA influx into the liver
in response to rapamycin might also play a role. In addition,
administration of rapamycin to mice lacking ERRa results in
a greater accumulation of TCA cycle intermediates compared
to ERRa-null mice alone. In contrast, treatment of WT mice
with rapamycin had no significant effect on the TCA cycle inter-
mediates measured possibly due to residual ERRa protein and
activity. The impaired mitochondrial potential in rapamycin-
treated ERRa-null mice suggests a decreased capacity to
oxidize lipids despite an observed upregulation in both Ppargc1a
and Ppara levels, and that excess citrate might be reoriented into
the lipid biosynthesis pathway. Moreover, as rapamycin induces
a diabetic-like state whereby excess energy may be converted
into fat, a defect in glucose handling may also be an underlying
cause in the observed lipid accumulation in response to rapamy-
cin. Although ERRa is recruited to and can regulate genes of the
glycolysis/gluconeogenesis pathway and loss of ERRa corre-
lates with improved insulin sensitivity and glucose tolerance in
rodent models (Charest-Marcotte et al., 2010; Dufour et al.,r empty vector (–) or a vector expressing Ubb for 96 hr. Tubulin levels are shown
her empty vector (–) or a vector expressing Stub1 for 96 hr as in (B).
, mTOR, ERRa, and the ubiquitin/proteasome system.
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rapamycin-induced glucose intolerance in mice. Overall, the
data indicate that the exacerbation of rapamycin-induced
NAFL in ERRa-null mice compared to WT results from a combi-
nation of factors including an increased potential to synthesize
lipids, a decreased efficacy in the export of TGs from the liver,
and a decreased mitochondrial capacity to metabolize lipids.
The mTOR signaling pathway is one of the major molecular
mechanisms controlling protein synthesis and energy metabo-
lism. Recent studies have attributed a nuclear function to
mTOR in the transcriptional control of metabolic genes and
protein synthesis. However, only a few target genes have
been identified to date, and the physiological pathways gov-
erned by this transcriptional mechanism remained largely
unknown. Our data now show that mTOR specifically targets
a large subset of pol-III-transcribed genes (e.g., tRNAs and
4.5S RNAs), supporting its role in protein translation. In addition,
mTOR targets a wide-range of pol-II-driven gene programs
involved in immune signaling, insulin receptor signaling, cancer
signaling pathways, and the ubiquitin/proteasome pathway, as
well as OXPHOS and FA metabolism. The mechanisms by
which mTOR regulates transcription of these gene networks
remains to be elucidated. However, mTOR occupancy of
promoter regions was found to be sensitive to both rapamycin
and the presence of Raptor, suggesting the involvement of
mTORC1 in this molecular process. While it has been previously
shown that mTOR can act as a cofactor through phosphoryla-
tion of transcription factors such as MAF1 and YY1 (Bla¨ttler
et al., 2012; Shor et al., 2010), our observation that a clear
consensus motif associated with mTOR binding events in the
mouse liver genome could not be identified supports the
concept that mTOR is a pluripotent cofactor that works with
several DNA-binding transcription factors.
Our results demonstrate that ERRa acts downstream of the
mTOR signaling pathway and may participate in the mTOR-
dependent response toward nutrient availability and energy
sensing. We show that rapamycin treatment, which is known
to mimic amino-acid-like starvation (Peng et al., 2002), modu-
lates ERRa metabolic target genes (e.g., Idh3a and Ogdh), sup-
porting a role for ERRa as a component of the mTOR signaling
pathway. Although it is clear that loss of ERRa exacerbates ra-
pamycin-induced NAFL, absence of ERRa alone is not suffi-
cient to induce dyslipidemia supporting the requirement for
a loss of mTOR activity and the implication of other metabolic
regulators in this process. Of note, while the elevated levels of
Esrrg observed in ERRa-null livers could counteract for the
absence of ERRa activity, this compensatory mechanism is
lost upon rapamycin treatment (Figure S6A). Indeed, in a manner
similar to that observed for ERRa, mTOR inhibition results in the
loss of ERRg in hepatocytes (Figures S6B–S6D). Furthermore, it
is well known that mTOR controls energy metabolism through
the regulation of SREBP-1. In vitro analyses report an increase
in SREBP-1 activity along with the induction of lipogenic genes
in an mTORC1- and AKT-dependent manner (Porstmann et al.,
2008; Yamauchi et al., 2011). Likewise, studies using adipocyte
cell lines demonstrated that mTOR inhibition reduced the
mRNA and protein levels of PPARg. In our work, although rapa-
mycin treatment triggered Pparg expression, it did not affect
Srebp1 expression despite a higher level of P-AKT. These596 Cell Metabolism 17, 586–598, April 2, 2013 ª2013 Elsevier Inc.results are consistent with published data obtained from
adipose tissues of rats treated with rapamycin (Blanchard
et al., 2012).
An unanticipated finding of our study is that rapamycin regu-
lates ERRa activity by targeting the receptor for degradation.
Our results demonstrate that ERRa is degraded by the nonlyso-
somal ubiquitin/proteasome system in response to rapamycin
and that this effect can be reversed by the proteasome inhibitor
MG132. In particular, ChIP-seq and functional analyses revealed
that mTOR is recruited to a significant number of genes involved
in this process and show that it can repress a subset of these
genes, providing a molecular mechanism for the observed rapa-
mycin-induced ERRa degradation in the proteasome. Indeed,
rapamycin inhibition of mTOR can promote ubiquitin-conjuga-
tion and the degradation of proteins such as Cyclin D1/3 and
nitric oxide synthetase (iNOS) (Chotechuang et al., 2011; Gar-
cı´a-Morales et al., 2006; Harston et al., 2011; Jin et al., 2009).
Our work now directly implicates mTOR in this process as
a negative transcriptional regulator of the ubiquitination pathway
and, together with its known repressive action on autophagy
(Kim et al., 2011; Yu et al., 2010), enhances the understanding
of its ability to repress protein degradation.
The results presented herein have an important clinical rele-
vance, as analogs of rapamycin (e.g., sirolimus) are commonly
used to treat cancer or as immunosuppressants to help pre-
vent the rejection of organ transplants. A significant number of
patients treated with these molecules develop associated side
effects, including insulin resistance and hepatic hyperlipidemia,
also referred to as a diabetes-like syndrome (Levy et al., 2006;
Morrisett et al., 2002). Therefore, a better control of glucose
homeostasis in these rapamycin-treated individuals has been
proposed, in particular by employing antidiabetic drugs as ther-
apeutic strategies to prevent rapalog-induced diabetes (Bla¨ttler
et al., 2012; Yang et al., 2012). Prior to this study, the use of
selective ERRa inverse agonists to improve insulin sensitivity
might have been considered to help counteract these side
effects (Handschin and Mootha, 2005; Patch et al., 2011).
However, genetic and pharmacological evidence presented in
this study suggest that treatment of patients with agents inhibit-
ing ERRa, in combination with mTOR inhibitors, would exacer-
bate the development of NAFLs. Therefore, considering that
ERRa-dependent control of metabolic gene programs is rapa-
mycin sensitive, strategies aimed at enhancing rather than
repressing ERRa activity appear to be a viable therapeutic
avenue to relieve hepatic hyperlipidemia and steatosis observed
in patients treated with mTOR inhibitors.EXPERIMENTAL PROCEDURES
Animals
Two- to 3-month-old male WT, ERRa/, and Raptor+/ mice in a C57BL/6J
genetic background were housed and fed standard chow in an animal facility
at McGill University. All mouse manipulations were performed in accordance
with the McGill Facility Animal Care Committee and the CCAC. See the
Supplemental Experimental Proceduresfor further details.
Metabolomics Analysis
Metabolomics studies were performed at the Metabolomics Core Facility at
McGill University. See the Supplemental Experimental Procedures for further
details.
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ERRa/mTOR Regulatory Axis in LiverStandard ChIP and ChIP Sequencing
mTOR and ERRa standard ChIP enrichments in mouse liver or Hepa 1-6 cells
were quantified by qPCR analysis using specific primers and normalized to the
average enrichments obtained with two control primer sets amplifying non-
mTOR- and -ERRa-bound genomic regions (Tables S6 and S7). For a more
detailed description, see the Supplemental Experimental Procedures.
Statistical Analysis
For the comparison between two or three experimental groups, statistical
significance was assessed via Student’s t test or one-way ANOVA with a
Tukey’s post test, respectively. Error bars represent ± SEM.
Histology, Biochemistry Measurements, Immunoprecipitation and
Western Blotting, Plasmid Transfections, siRNA, Lentiviral shRNA
Silencing, and Cell Culture and Reagents
See the Supplemental Experimental Procedures.
ACCESSION NUMBERS
ChIP-seq data have been deposited in the NCBI Gene Expression Omnibus
(GEO; http://www.ncbi.nlm.nih.gov/geo/) under the accession number
GSE43638.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, eight tables, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.cmet.2013.03.003.
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